End-stage renal disease related to AA amyloidosis is well characterized but there is limited data concerning patient and graft outcomes after renal transplantation. The aim of this study is to evaluate the clinical features of, and risk factors for recurrent AA amyloidosis, as well as the effects of these factors on the ultimate outcome of renal allografts.
AA amyloidosis is a rare but serious complication of several chronic inflammatory diseases including recurrent hereditary periodic fever syndromes. Although end-stage renal disease related to AA amyloidosis is well characterized, there is limited data concerning patient and graft outcomes after renal transplantation, with most of the findings reported from small series. Recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing graft and patient outcomes in larger study groups will bring better understanding and new strategies in daily practice.
Study Type
OBSERVATIONAL
Enrollment
54
Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine
Bursa, Turkey (Türkiye)
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
Istanbul, Turkey (Türkiye)
Division of Nephrology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine
Istanbul, Turkey (Türkiye)
Division of Nephrology, Sisli Hamidiye Etfal Training and Education Hospital
Istanbul, Turkey (Türkiye)
Allograft survival
Time frame: 1 - 5 years
Allograft rejection
Time frame: 1 - 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.